[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630472":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":21,"centralContacts":22,"locations":28,"responsibleParty":47,"collaborators":21,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":54,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":59,"enrollmentInfo":60,"targetDuration":21,"studyType":63,"phases":64,"briefSummary":66,"conditions":67,"keywords":21,"overallStatus":31,"whyStopped":21,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":78},{"fullName":5,"class":6},"University Hospital, Toulouse","OTHER",[8,13],{"label":9,"type":10,"description":9,"interventionNames":11},"patients with Autoimmune encephalitis","EXPERIMENTAL",[12],"Other: TEP with radioligand EAI 714",{"label":14,"type":10,"description":14,"interventionNames":15},"control",[12],[17],{"type":6,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"TEP with radioligand EAI 714","60-minutes \\[18F\\]-DPA-714 PET imaging",[14,9],null,[23],{"name":24,"role":25,"phone":26,"phoneExt":21,"email":27},"Marie Rafiq, MD","CONTACT","+33 561779491","rafiq.m@chu-toulouse.fr",[29],{"facility":30,"status":31,"city":32,"state":21,"zip":21,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"University Hospital","RECRUITING","Toulouse","France","FR",{"type":36,"coordinates":37},"Point",[38,39],1.44367,43.60426,{"lat":39,"lon":38},[42,44],{"name":43,"role":25,"phone":21,"phoneExt":21,"email":27},"Marie RAFIQ, MD",{"name":45,"role":46,"phone":21,"phoneExt":21,"email":21},"Marie rafiq, MD","PRINCIPAL_INVESTIGATOR",{"type":48,"investigatorFullName":21,"investigatorTitle":21,"investigatorAffiliation":21,"oldNameTitle":21,"oldOrganization":21},"SPONSOR","100630472","phase-2-is-18f-dpa-714-pet-a-good-marker-of-neuroinflammation-in-autoimmune-encephalitis-100630472",false,"NCT07488117","Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?","EAI-714","Inclusion Criteria:\n\n* Age 18-80 years;\n* meeting clinical criteria for \"possible\" AE with identified antibodies;\n* newly diagnosed with symptoms \\\u003C6 months;\n* no second-line immunosuppressive treatment;\n* high or mixed TSPO binding affinity phenotype.\n\nExclusion Criteria:\n\n* Pregnant women;\n* contraindications to MRI;\n* known allergic reaction to \\[18F\\]-DPA-714; legal protection measure;\n* paraneoplastic syndrome following immune checkpoint inhibitor therapy.",true,"ALL","18 Years","80 Years",{"count":61,"type":62},40,"ESTIMATED","INTERVENTIONAL",[65],"PHASE2","This study aims to evaluate the effectiveness of \\[18F\\]-DPA-714 PET imaging in detecting neuroimmune activity in patients with autoimmune encephalitis (AE). The primary objective is to compare \\[18F\\]-DPA-714 binding in AE patients to healthy controls.",[68],"Autoimmune Encephalitis (AE)","2026-05-06",{"date":71,"type":72},"2026-05-11","ACTUAL",{"date":74,"type":72},"2026-03-31",{"date":76,"type":62},"2028-01",{"name":5,"class":6},1]